AuthorHarryman, William L (a)
Hinton, James P (b)
Rubenstein, Cynthia P (b)
Singh, Parminder (a)
Nagle, Raymond B (a)
Parker, Sarah J (c)
Knudsen, Beatrice S (c)
Cress, Anne E (a)
AffiliationThe University of Arizona Cancer Center
Cancer Biology Graduate Program
Cedars Sinai Medical Center
MetadataShow full item record
PublisherELSEVIER SCIENCE BV
CitationThe Cohesive Metastasis Phenotype in Human Prostate Cancer. 2016, 1866 (2):221-231 Biochim. Biophys. Acta
JournalBiochimica et biophysica acta
Rights© 2016 Published by Elsevier B.V.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractA critical barrier for the successful prevention and treatment of recurrent prostate cancer is detection and eradication of metastatic and therapy-resistant disease. Despite the fall in diagnoses and mortality, the reported incidence of metastatic disease has increased 72% since 2004. Prostate cancer arises in cohesive groups as intraepithelial neoplasia, migrates through muscle and leaves the gland via perineural invasion for hematogenous dissemination. Current technological advances have shown cohesive-clusters of tumor (also known as microemboli) within the circulation. Circulating tumor cell (CTC) profiles are indicative of disseminated prostate cancer, and disseminated tumor cells (DTC) are found in cohesive-clusters, a phenotypic characteristic of both radiation- and drug-resistant tumors. Recent reports in cell biology and informatics, coupled with mass spectrometry, indicate that the integrin adhesome network provides an explanation for the biophysical ability of cohesive-clusters of tumor cells to invade thorough muscle and nerve microenvironments while maintaining adhesion-dependent therapeutic resistance. Targeting cohesive-clusters takes advantage of the known ability of extracellular matrix (ECM) adhesion to promote tumor cell survival and represents an approach that has the potential to avoid the progression to drug- and radiotherapy-resistance. In the following review we will examine the evidence for development and dissemination of cohesive-clusters in metastatic prostate cancer.
Note12 month embargo; available online 24 September 2016
VersionFinal accepted manuscript
SponsorsNIH grants RO1 CA159406 (AEC), RO1 CA131255 (BSK), P50 CA092131 (BSK), K99HL128787 (SJP), T32 CA09213, and P30 CA23074 and P50 CA092131. Other support included DoD-PC131996 (BSK), Prostate Cancer Foundation Creativity Award (BSK), and the Steven Spielberg Team Science Award (BSK).
- Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.
- Authors: Rubenstein CS, Gard JMC, Wang M, McGrath JE, Ingabire N, Hinton JP, Marr KD, Simpson SJ, Nagle RB, Miranti CK, Warfel NA, Garcia JGN, Arif-Tiwari H, Cress AE
- Issue date: 2019 Sep 15
- The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion.
- Authors: Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE
- Issue date: 2010 Aug
- Targeting anoikis resistance in prostate cancer metastasis.
- Authors: Sakamoto S, Kyprianou N
- Issue date: 2010 Apr
- Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
- Authors: Pavese JM, Bergan RC
- Issue date: 2014 Oct 1
- Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance.
- Authors: Sakamoto S, McCann RO, Dhir R, Kyprianou N
- Issue date: 2010 Mar 1